209 related articles for article (PubMed ID: 15575031)
1. A bitter pill: formulary variability and the challenge to prescribing physicians.
Shrank WH; Ettner SL; Glassman P; Asch SM
J Am Board Fam Pract; 2004; 17(6):401-7. PubMed ID: 15575031
[TBL] [Abstract][Full Text] [Related]
2. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiered prescription copayments on the use of preferred brand medications.
Rector TS; Finch MD; Danzon PM; Pauly MV; Manda BS
Med Care; 2003 Mar; 41(3):398-406. PubMed ID: 12618643
[TBL] [Abstract][Full Text] [Related]
4. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
[TBL] [Abstract][Full Text] [Related]
5. The effect of a three-tier formulary on antidepressant utilization and expenditures.
Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
[TBL] [Abstract][Full Text] [Related]
6. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
7. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
8. General practitioners choose within a narrow range of drugs when initiating new treatments: a cohort study of cardiovascular drug formularies.
Buusman A; Kragstrup J; Andersen M
Eur J Clin Pharmacol; 2005 Oct; 61(9):651-6. PubMed ID: 16187132
[TBL] [Abstract][Full Text] [Related]
9. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
[TBL] [Abstract][Full Text] [Related]
10. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
Wang YR; Pauly MV
Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891
[TBL] [Abstract][Full Text] [Related]
11. Are incentive-based formularies inversely associated with drug utilization in managed care?
Gleason PP; Gunderson BW; Gericke KR
Ann Pharmacother; 2005 Feb; 39(2):339-45. PubMed ID: 15644478
[TBL] [Abstract][Full Text] [Related]
12. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
Fairman KA; Motheral BR; Henderson RR
Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
[TBL] [Abstract][Full Text] [Related]
13. Formulary management in the Department of Defense.
Trice S; Devine J; Mistry H; Moore E; Linton A
J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor blockers on the formularies of Medicare drug plans.
Gellad WF; Huskamp HA; Phillips KA; Haas JS
J Gen Intern Med; 2007 Aug; 22(8):1172-5. PubMed ID: 17503103
[TBL] [Abstract][Full Text] [Related]
15. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
Mullins CD; Palumbo FB; Saba M
Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
[TBL] [Abstract][Full Text] [Related]
16. Formulary tiers, medication cost sharing, and transparency in bronze and silver qualified health plans in 2014 vs 2018.
Hung A; Sauvageau G
J Manag Care Spec Pharm; 2021 Oct; 27(10):1332-1340. PubMed ID: 34595951
[No Abstract] [Full Text] [Related]
17. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
18. Approaches to pharmacy benefit management and the impact of consumer cost sharing.
Olson BM
Clin Ther; 2003 Jan; 25(1):250-72. PubMed ID: 12637125
[TBL] [Abstract][Full Text] [Related]
19. Controlling prescription drug expenditures: a report of success.
Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
[TBL] [Abstract][Full Text] [Related]
20. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
